For example, van Elsas et al. demonstrated that in the context of a poorly immunogenic B16F10 melanoma model, effective anti-CTLA-4 therapy required the administration of a GM-CSF expressing cell vaccine alongside checkpoint blockade to achieve appreciable impact [119]. This evidence concerns the gene CSF2 and melanoma.